

Article

Total Synthesis of Anmindenol A and Its Application to the Design, Synthesis, and Biological Evaluation of Derivatives Thereof

Jeyun Jo, Myeonggyo Jeong, Ji-Su Ahn, Jinia Akter, Hyung-Sik Kim, Young-Ger Suh, and Hwayoung Yun

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b01564 • Publication Date (Web): 30 Jul 2019

Downloaded from pubs.acs.org on July 30, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Total Synthesis of Anmindenol A and Its Application to the Design, Synthesis, and Biological Evaluation of Derivatives Thereof

Jeyun Jo,^{†,‡} Myeonggyo Jeong,^{†,‡} Ji-Su Ahn,[‡] Jinia Akter,[†] Hyung-Sik Kim,[‡] Young-Ger Suh[§] and Hwayoung Yun^{*,†}

[†] College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea

[‡] Department of Life Science in Dentistry, School of Dentistry, Pusan National University, Yangsan 50612, Republic of Korea


[§] College of Pharmacy, CHA University, 120 Haeryong-ro, Pocheon-si, Gyeonggi-do 11160, Republic of Korea

[†] These authors contributed equally to this work.

CORRESPONDING AUTHOR

* E-mail: hyun@pusan.ac.kr (H. Yun)

TABLE OF CONTENTS



ABSTRACT


The first total synthesis of anmindenol A is described in four steps. A notable feature of the synthetic route includes the efficient construction of the 3,10-dialkylsubstituted benzofulvene core via a stereoselective vinylogous Stork enamine aldol condensation. The strategy provided a blueprint for the practical preparation of derivatives with modifications in the C-10 alkyl substituents. The novel derivatives inhibited nitric oxide production in stimulated RAW 264.7 macrophage cells.

of anmindenol A (**1**) through a stereoselective VSEAC, its application to the synthesis of a novel series of rationally designed 3,10-dialkylbenzofulvene derivatives, and biological evaluation of the synthesized compounds.


RESULTS AND DISCUSSION

Our retrosynthetic route for anmindenol A (**1**) and its regioisomer **7** is outlined in Scheme 1. The synthetic plan intended to utilize vinylogous Stork enamine aldol condensations of the enamine precursors **10** and **11** to construct the highly functionalized (*E,Z*)- δ -*i*Pr- $\alpha,\beta,\gamma,\delta$ -unsaturated aldehydes **8** and **9**. The final benzofulvenes **1** and **7** could be readily obtained by Luche reduction⁹ of the corresponding aldehydes **8** and **9** followed by Negishi cross-coupling with dimethylzinc.¹⁰ Both enamine **10** and **11** were expected to be conveniently prepared as regioisomers from commercially available indanone **12**.


Scheme 1. Retrosynthesis of anmindenol A (**1**) and its regioisomer **7**.



In order to prepare enamine precursors for VSEAC, we initially commenced the synthesis using indanone **13**, which had a methyl group inserted at the C-6 (Scheme 2). Exposure of **13** to NaBH₄ and the dehydration of the resulting alcohol **14** with *p*-toluenesulfonic acid afforded indene **15**.¹¹ Subsequent solvent-free condensation of **15** with *N,N*-dimethylformamide dimethyl acetal (DMF-DMA) smoothly provided the enamine precursors **16** and **17** in a ratio of almost 1:1 in 81% combined yield.¹² Unfortunately, these regioisomers were inseparable by column chromatography. Thus, we circumvented the unexpected problem by employing 6-bromo-1-indanone (**12**) as a starting material, which was strategically advantageous not only to form stable enamines¹³ but also to introduce a missing methyl group to the final benzofulvenes at the late stage. The same three-step sequence of **12** enabled to furnish the separable enamines **10** and **11** in a high yield (1.15:1 ratio by ¹H NMR analysis).

Scheme 2. Preparation of enamine precursors **10** and **11**.

With the stable enamine **10** in hand, we have investigated to determine the optimal reaction conditions for VSEAC (Table 1). Gratifyingly, an initial attempt with isobutyraldehyde stereoselectively resulted in the desired aldehyde **8** in a 7:1 *E/Z* ratio in a moderate yield under the relevant conditions (Table 1, entry 1).^{8a} Encouraged by this result, further evaluation of different parameters, such as reagent, temperatures, concentration, and solvent, was performed to improve the stereoselectivity and productivity. Previous studies by Lash *et al.* showed that TiCl₄ as a Lewis acid is also applicable to vinylogous-type Claisen-Schmidt condensation.^{2a} However, the use of TiCl₄ gave very low yield of the desired product **8** with the lower stereoselectivity (Table 1, entry 2). Although higher temperature (reflux) accelerated the reaction rate, no significant changes were observed (Table 1, entry 3). In addition, cooling the reaction temperature to -20 °C decreased the yield and stereoselectivity (Table 1, entry 4). Subsequently, we manipulated the reaction by increasing the enamine concentration by 10 times to allow eco-friendly scale-up synthesis,¹⁴ however, the yield and stereoselectivity of aldehyde **8** were slightly diminished (Table 1, entry 5). Notably, switching the reaction solvent to THF led to greatly improved yield with the consistent stereoselectivity (Table 1, entry 6). Taken together, we concluded that the optimal reaction conditions are those in entry 6.


Table 1. Optimization of VSEAC of enamine **10** with isobutyraldehyde.

entry	Lewis acid	solvent	conc.(N) ^a	temp.	time	yield ^b (<i>E/Z</i> ratio) ^c
1	Bu ₂ BOTf	DCM	0.005	rt	4 h	65% (7 : 1)
2	TiCl ₄	DCM	0.005	rt	14 h	7% (4.5 : 1)
3	Bu ₂ BOTf	DCM	0.005	reflux	3 h	62% (6 : 1)
4	Bu ₂ BOTf	DCM	0.005	-20 °C	24 h	16% (4.5 : 1)
5	Bu ₂ BOTf	DCM	0.05	rt	4 h	44% (5.5 : 1)
6	Bu ₂ BOTf	THF	0.05	rt	3 h	77% (7 : 1)

^aConcentration of the enamine **10**. ^bIsolated yield. ^cThe *E/Z* ratio of product was determined by ¹H NMR.

Having successfully constructed the benzofulvene sesquiterpenoid skeleton, we then explored the total synthesis of anmindenol A (**1**) and its regioisomer **7** (Scheme 3). $\alpha,\beta,\gamma,\delta$ -Unsaturated aldehyde **8** was carefully reduced with NaBH₄ and CeCl₃·7H₂O under the cooled condition, providing alcohol **20** in 80% yield.⁹ Subsequent Negishi cross-coupling of 6-bromobenzofulvene **20** with Me₂Zn in the presence of Pd(PPh₃)₄ finally rendered anmindenol A (**1**) in high yield.¹⁰ The structure of **1** was confirmed through comparison of its spectra (¹H NMR and ¹³C{¹H} NMR) with those reported in the literature.^{3a} Next, synthesis of **7** commenced from the enamine **11**, which was previously prepared in Scheme 2. The precursor **11** was successfully converted into benzofulvene aldehyde **9** in an 8:1 *E/Z* ratio in 71% yield under the established procedure. Finally, Luche reduction of **9**, followed by Negishi cross-coupling produced the regioisomer **7** in an excellent yield.


Scheme 3. Total syntheses of anmindenol A (**1**) and its regioisomer **7**.



Our synthetic efforts of the benzofulvene sesquiterpenoids **1** and **7** simultaneously led us into such a journey of discovering novel analogs with potent biological activities. A molecular modeling study revealed that the hydroxy group of anmindenol A tends to form a hydrogen bond with a crucial residue of iNOS (Supporting Information).¹⁵ Therefore, our derivatization was focused on the modification of the isopropyl group at C-10 to decipher the effect of alkyl substituents on iNOS inhibition.

Initially, we explored the substrate scope of the VSEAC between enamines **10** and **11** and several alkyl aldehydes (Table 2). Fortunately, all condensations proceeded smoothly and resulted in good to moderate yields. In the case of one- or two-carbon truncated aldehydes, the *E/Z* ratios were slightly decreased to approximately 4:1, compared with those in the synthetic results of **8** and **9** (Table 2, entries 1-4). In particular, the condensation with pivalaldehyde, which was decorated with an additional one-carbon, gave the desired *E*-isomer only (Table 2, entries 5 and 6). These results indicated that the stereoselectivity of our VSEAC was presumably affected by the steric property of alkyl aldehydes.

Table 2. VSEAC of enamine substrates **10** and **11** with alkyl aldehydes.




entry	enamine	aldehyde	product	yield ^a (<i>E/Z</i> ratio) ^b
1	10	acetaldehyde	22	57% (4.5 : 1)
2	11	acetaldehyde	23	68% (4 : 1)
3	10	propionaldehyde	24	42% (4.5 : 1)
4	11	propionaldehyde	25	35% (4 : 1)
5	10	pivalaldehyde	26	39% (<i>E</i> -isomer only)
6	11	pivalaldehyde	27	57% (<i>E</i> -isomer only)

^aIsolated yield. ^bThe *E/Z* ratio of product was determined by ¹H NMR.

With the carefully purified *E* stereoisomers **22-27** in hand, we then executed syntheses of novel derivatives of natural benzofulvene anmindenol A for the construction of a structurally unexplored chemical library. As depicted in Scheme 4, reductions of aldehydes **22-27** under Luche condition and Negishi cross-couplings of the resultant alcohols **28-33** with Me₂Zn successfully afforded the final analogs **34-39** in high yields.

Scheme 4. Syntheses of anmindenol A analogs **34-39**.



In order to assess the iNOS inhibitory activities of newly synthesized anmindenol A and its analogs, all compounds including structurally closely related intermediates **20** and **21** were tested against lipopolysaccharide (LPS)-activated macrophage RAW264.7 cells in a dose-dependent manner.¹⁶ The results of the biological evaluation are shown in Table 3. Anmindenol A (**1**) as a positive control inhibited nitric oxide production with an IC₅₀ value of 33.6 μM nearly equal to the previously reported value.^{3a} In general, most of the novel derivatives exhibited slightly improved activities (IC₅₀ = 17.3–35.5 μM) compared to that of **1**, which presumably indicated that the benzofulvene moiety played a crucial role in the iNOS inhibitory activity of the compounds. Interestingly, one-carbon-truncated analog **36** showed approximately 2-fold higher potency to the natural product **1**. Moreover, among the regioisomers, one-carbon-truncated analog **37** also displayed the highest activity against NO release.

Table 3. Inhibitory effects of the synthesized compounds on NO production.

comp.	IC ₅₀ (μM)	comp.	IC ₅₀ (μM)
1	33.6	7	22.7
20	18.4	21	33.0
34	28.3	35	23.3

36	17.3	37	21.5
38	21.2	39	35.5

CONCLUSION

In conclusion, we have accomplished the first total synthesis of rare benzofulvene sesquiterpenoid anmindenol A (**1**) (27% overall yield) in only four steps from the known indene **19**. The key feature of our synthesis includes the stereoselective construction of the 3,10-dialkylsubstituted benzofulvene backbone utilizing a vinylogous Stork enamine aldol condensation. The developed synthetic strategy was applied to synthesize unexplored derivatives of **1**, which were rationally designed by using computational docking analysis. The synthesized 3,10-dialkylbenzofulvenes were evaluated for their iNOS inhibitory activities in stimulated RAW 264.7 macrophage cells. The findings in this work suggested that benzofulvene-based compounds may have a chance to be developed as a potential anti-inflammatory or anti-senescence agents. Employing this practical synthetic route, our further studies toward syntheses of other natural benzofulvenes and evaluation of their biological activities are currently underway.

EXPERIMENTAL SECTION

General Experimental Procedure

Unless noted otherwise, all starting materials and reagents were obtained from commercial suppliers and were used without further purification. Reaction flasks were dried at 100 °C. Air- and moisture-sensitive reactions were performed under argon atmosphere. All solvents used for routine isolation of products and chromatography were reagent grade. Flash column chromatography was performed using silica gel 60 (230-400 mesh, Merck) with the indicated solvents. Thin-layer chromatography was performed using 0.25 mm silica gel plates (Merck). ¹H and ¹³C{¹H} NMR spectra were recorded on Varian Unity 400, AVANCE NEO 500 and Unity-Inova 500 as solutions in the indicated solvents. Chemical shifts were expressed in parts per million (ppm, δ) downfield from tetramethylsilane and were referenced to the deuterated solvent. ¹H NMR data were reported in the order of chemical shift, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet and/or multiple resonance), number of protons, and coupling constant in hertz (Hz). Infrared (IR) spectra were obtained by an FT/IR spectrometer and are reported as absorption wavenumbers (cm⁻¹). High resolution mass spectra were obtained with an Agilent 6530 Accurate-Mass Q-TOF and a JEOL JMS-AX 505WA instrument.

6-Methyl-2,3-dihydro-1H-inden-1-ol (14).¹⁷ To a solution of 6-methyl-1-indanone (526 mg, 3.60 mmol) in EtOH (12.0 mL) was added NaBH₄ (136 mg, 3.60 mmol) at ambient temperature. After being stirred for 1 h at the same temperature, the reaction mixture was quenched with saturated NH₄Cl and then concentrated in vacuo. The residue was extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 5) to

1
2
3 afford 522 mg (98%) of alcohol **14** as white solid: $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ 7.23 (s, 1H), 7.15 (d, 1H, $J = 7.7$ Hz), 7.09 (d, 1H, $J = 7.7$
4 Hz), 5.20 (q, 1H, $J = 6.2$ Hz), 3.02 (m, 1H), 2.78 (m, 1H), 2.48 (m, 1H), 2.37 (s, 3H), 1.94 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ
5 145.2, 140.4, 136.5, 129.3, 124.8, 124.7, 76.5, 36.2, 29.5, 21.4.

6
7
8 *5-Methyl-1H-indene (15)*.¹¹ To a solution of alcohol **14** (502 mg, 3.38 mmol) in benzene (14.0 mL) was added PTSA·H₂O (64.4 mg, 0.338
9 mmol) at ambient temperature. After being stirred for 3 h at 65 °C, the reaction mixture was quenched with saturated NaHCO₃ and then
10 extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash
11 column chromatography on silica gel (*n*-hexane) to afford 279 mg (63%) of **15** as a colorless oil: $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ 7.36 (d, 1H,
12 $J = 7.6$ Hz), 7.23 (s, 1H), 7.02 (d, 1H, $J = 7.5$ Hz), 6.84 (m, 1H), 6.54 (m, 1H), 3.36 (s, 2H), 2.40 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz)
13 δ 145.2, 140.8, 135.9, 134.6, 132.1, 125.5, 123.5, 121.8, 38.8, 21.6.

14
15
16
17
18 (*E*)-*N,N*-Dimethyl-1-(5-methyl-1H-inden-1-ylidene)methanamine (**16**) and (*E*)-*N,N*-dimethyl-1-(6-methyl-1H-inden-1-
19 ylidene)methanamine (**17**). To an indene **15** (81.0 mg, 0.622 mmol) was added DMF-DMA (83.0 μL , 0.622 mmol) at ambient temperature.
20 After being stirred for 17 h at 100 °C, the reaction mixture was quenched with H₂O and then extracted with EtOAc. The combined organic
21 layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc /
22 *n*-hexane = 1 : 5, TEA 2%) to afford 93.6 mg (81% yield as a 1 : 1 regioisomeric enamine mixture) of **16** as brown solid: FT-IR (thin film,
23 neat) ν_{max} 3001, 2913, 2859, 1705, 1625, 1489, 1451, 1439, 1408, 1384, 1336 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ (mixture of regioisomer
24 **17**) 7.51 (d, 1H, $J = 7.9$ Hz), 7.43 (s, 1H), 7.39 (m, 2H), 7.37 (s, 1H), 7.31 (s, 1H), 7.05 (d, 1H, $J = 5.1$ Hz), 7.01 (d, 1H, $J = 5.4$ Hz), 7.00
25 (m, 1H), 6.98 (m, 1H), 6.81 (m, 2H), 3.25 (s, 6H), 3.24 (s, 6H), 2.48 (s, 3H), 2.46 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ (mixture of
26 regioisomer **17**) 140.3, 140.2, 138.5, 138.4, 135.8, 135.7, 131.8, 131.4, 123.7, 123.3, 123.0, 122.1, 121.7, 121.7, 120.7, 120.0, 116.5, 115.7,
27 109.8, 109.7, 43.5, 22.0, 21.7; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for C₁₃H₁₆N 186.1277; Found 186.1277.

28
29
30
31
32
33
34
35 *6-Bromo-2,3-dihydro-1H-inden-1-ol (18)*.¹¹ To a solution of indanone **12** (5.00 g, 23.7 mmol) in EtOH (250 mL) was added NaBH₄ (806
36 mg, 21.3 mmol) at ambient temperature. After being stirred for 12 h at the same temperature, the reaction mixture was quenched with
37 saturated NH₄Cl and then concentrated in vacuo. The residue was extracted with EtOAc. The combined organic layers were dried over
38 MgSO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 4) to
39 afford 4.86 g (96%) of **18** as white solid: $^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ 7.52 (s, 1H), 7.36 (dd, 1H, $J = 8.0, 1.7$ Hz), 7.11 (d, 1H, $J = 8.0$ Hz),
40 5.21 (q, 1H, $J = 6.4$ Hz), 2.98 (m, 1H), 2.75 (m, 1H), 2.49 (m, 1H), 1.94 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 147.4, 142.3, 131.4,
41 127.6, 126.6, 120.4, 76.2, 36.3, 29.5.

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5-Bromo-1H-indene (19).¹¹ To a solution of alcohol **18** (4.47 g, 21.0 mmol) in benzene (150 mL) was added PTSA·H₂O (399 mg, 2.10
mmol) at ambient temperature. After being stirred for 14 h at 65 °C, the reaction mixture was quenched with saturated NaHCO₃ and then
extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash
column chromatography on silica gel (*n*-hexane) to afford 3.58 g (88%) of **19** as a colorless oil: $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ 7.54 (s, 1H),
7.32 (m, 2H), 6.82 (m, 1H), 6.60 (m, 1H), 3.36 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 147.1, 142.5, 136.1, 131.4, 127.4, 125.1, 124.2,
120.4, 38.9.

(E)-1-(5-Bromo-1*H*-inden-1-ylidene)-*N,N*-dimethylmethanamine (**10**) and *(E)*-1-(6-Bromo-1*H*-inden-1-ylidene)-*N,N*-dimethylmethanamine (**11**). To an indene **19** (330 mg, 1.69 mmol) was added DMF-DMA (226 μ L, 1.69 mmol) at ambient temperature. After being stirred for 12 h at 100 $^{\circ}$ C, the reaction mixture was quenched with H₂O and then extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 3) to afford 417 mg (99%) of **10** and **11** as a 1.15 : 1 mixture.

Compound **10**: Brown solid; FT-IR (thin film, neat) ν_{\max} 2917, 1623, 1587, 1447, 1383, 1327 cm^{-1} ; ¹H NMR (CDCl₃, 400 MHz) δ 7.58 (d, 1H, *J* = 1.7 Hz), 7.44 (d, 1H, *J* = 8.2 Hz), 7.41 (s, 1H), 7.20 (dd, 1H, *J* = 8.3, 1.8 Hz), 7.07 (d, 1H, *J* = 5.2 Hz), 6.75 (d, 1H, *J* = 5.2 Hz), 3.29 (s, 6H); ¹³C {¹H} NMR (CDCl₃, 100 MHz) δ 141.6, 139.5, 136.5, 124.4, 124.0, 123.0, 120.4, 117.3, 115.7, 109.0, 43.7; HRMS (FAB+) *m/z*: [M]⁺ Calcd for C₁₂H₁₂BrN 249.0153; Found 249.0151.

Compound **11**: Brown solid; FT-IR (thin film, neat) ν_{\max} 2919, 1628, 1450, 1421, 1410, 1384, 1337 cm^{-1} ; ¹H NMR (CDCl₃, 500 MHz) δ 7.69 (m, 1H), 7.38 (s, 1H), 7.32 (d, 1H, *J* = 8.1 Hz), 7.20 (dd, 1H, *J* = 8.1, 1.7 Hz), 7.04 (d, 1H, *J* = 5.2 Hz), 6.77 (d, 1H, *J* = 5.1 Hz), 3.28 (s, 6H); ¹³C {¹H} NMR (CDCl₃, 100 MHz) δ 141.7, 139.8, 136.4, 124.8, 123.3, 121.6, 120.7, 119.0, 115.9, 108.8, 43.5; HRMS (FAB+) *m/z*: [M]⁺ Calcd for C₁₂H₁₂BrN 249.0153; Found 249.0146.

(E)-6-Bromo-1-(2-methylpropylidene)-1*H*-indene-3-carbaldehyde (**8**). To a solution of isobutyraldehyde (24.9 μ L, 0.273 mmol) in THF (4.10 mL) was added Bu₂BOTf (273 μ L of a 1.0 M solution in CH₂Cl₂) at ambient temperature. To a reaction mixture was immediately added a solution of enamine **10** (68.3 mg, 0.273 mmol) in THF (1.36 mL) via cannula. After being stirred for 3 h, the reaction mixture was quenched with H₂O and then extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 7) to afford 58.5 mg (77% yield, *E* : *Z* = 7 : 1) of aldehyde **8** as yellow solid: FT-IR (thin film, neat) ν_{\max} 2966, 2921, 2852, 2352, 2307, 1718, 1679, 1466 cm^{-1} ; ¹H NMR (CDCl₃, 500 MHz) δ 10.12 (s, 1H), 7.94 (d, 1H, *J* = 8.1 Hz), 7.75 (d, 1H, *J* = 1.7 Hz), 7.54 (s, 1H), 7.44 (dd, 1H, *J* = 8.1, 1.7 Hz), 6.84 (d, 1H, *J* = 10.3 Hz), 3.15 (m, 1H), 1.23 (d, 6H, *J* = 6.6 Hz); ¹³C {¹H} NMR (CDCl₃, 100 MHz) δ 188.9, 149.5, 140.7, 138.8, 136.4, 130.5, 124.1, 124.0, 122.8, 122.7, 120.7, 30.8, 23.1; HRMS (FAB+) *m/z*: [M + H]⁺ Calcd for C₁₄H₁₄BrO 277.0228; Found 277.0223.

(E)-(6-Bromo-1-(2-methylpropylidene)-1*H*-inden-3-yl)methanol (**20**). To a solution of aldehyde **8** (49.9 mg, 0.180 mmol) in EtOH (3.00 mL) was added a solution of CeCl₃·7H₂O (101 mg, 0.271 mmol), NaBH₄ (7.49 mg, 0.198 mmol) in EtOH (2.00 mL) dropwise at 0 $^{\circ}$ C. After being stirred for 1 h at the same temperature, the reaction mixture was quenched with 1N HCl and then concentrated in vacuo. The residue was extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 3) to afford 40.2 mg (80%) of alcohol **20** as yellow solid: FT-IR (thin film, neat) ν_{\max} 3361, 2960, 2927, 2868, 1712, 1647, 1595, 1448, 1416, 1316 cm^{-1} ; ¹H NMR (CDCl₃, 400 MHz) δ 7.69 (dd, 1H, *J* = 1.8, 0.5 Hz), 7.35 (dd, 1H, *J* = 8.0, 1.8 Hz), 7.17 (d, 1H, *J* = 7.9 Hz), 6.74 (m, 1H), 6.42 (dd, 1H, *J* = 10.0, 0.7 Hz), 4.73 (s, 2H), 3.02 (m, 1H), 1.96 (s, 1H), 1.16 (d, 6H, *J* = 6.6 Hz); ¹³C {¹H} NMR (CD₃OD, 100 MHz) δ 145.5, 141.4, 141.2, 141.0, 137.8, 130.4, 123.2, 122.4, 121.5, 120.1, 59.5, 30.8, 23.4; HRMS (FAB+) *m/z*: [M]⁺ Calcd for C₁₄H₁₅BrO 278.0306; Found 278.0299.

1
2
3 *Anmindenol A (1)*. To a solution of alcohol **20** (4.60 mg, 16.5 μ mol) in THF (300 μ L) was added a solution of Pd(PPh₃)₄ (3.0 mg, 2.60
4 μ mol) in THF (200 μ L) and Me₂Zn (41.3 μ L of a 1.2 M solution in toluene) at ambient temperature. After being refluxed for 2 h, the reaction
5 mixture was quenched with saturated NaHCO₃ and then extracted with EtOAc. The combined organic layers were dried over MgSO₄ and
6 concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 4) to afford 3.4 mg
7 (96%) of *anmindenol A (1)* as a yellow oil: FT-IR (thin film, neat) ν_{\max} 3370, 2960, 2924, 2867, 1708, 1648, 1607, 1464, 1362 cm⁻¹; ¹H
8 NMR (CDCl₃, 400 MHz) δ 7.41 (m, 1H), 7.21 (d, 1H, *J* = 7.6 Hz), 7.06 (ddd, 1H, *J* = 7.6, 1.5, 0.7 Hz), 6.70 (d, 1H, *J* = 1.0 Hz), 6.40 (dd,
9 1H, *J* = 9.9, 0.6 Hz), 4.76 (dd, 2H, *J* = 5.8, 0.9 Hz), 3.04 (m, 1H), 2.40 (s, 3H), 1.16 (d, 6H, *J* = 6.7 Hz); ¹³C{¹H} NMR (CDCl₃, 100 MHz)
10 δ 144.3, 138.7, 138.5, 138.1, 137.1, 135.2, 127.7, 120.5, 120.0, 118.8, 60.1, 29.7, 23.4, 21.8; HRMS (FAB+) *m/z*: [M]⁺ Calcd for C₁₅H₁₈O
11 214.1358; Found 214.1352.

12
13
14
15
16
17
18 *(E)-5-Bromo-1-(2-methylpropylidene)-1H-indene-3-carbaldehyde (9)*. To a solution of isobutyraldehyde (22.2 μ L, 0.243 mmol) in THF
19 (3.65 mL) was added Bu₂BOTf (243 μ L of a 1.0 M solution in CH₂Cl₂) at ambient temperature. To a reaction mixture was immediately
20 added a solution of enamine **11** (60.9 mg, 0.243 mmol) in THF (1.21 mL) via cannula. After being stirred for 3 h, the reaction mixture was
21 quenched with H₂O and then extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The
22 residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 7) to afford 48.9 mg (72% yield, *E* : *Z* = 8 : 1)
23 of aldehyde **9** as yellow solid: FT-IR (thin film, neat) ν_{\max} 2963, 2928, 2868, 2809, 2713, 1714, 1677, 1638, 1597, 1570, 1538, 1445, 1421,
24 1391, 1364, 1306 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 10.12 (s, 1H), 8.25 (d, 1H, *J* = 1.7 Hz), 7.58 (s, 1H), 7.48 (d, 1H, *J* = 8.1 Hz), 7.42
25 (dd, 1H, *J* = 8.1, 1.8 Hz), 6.84 (d, 1H, *J* = 10.3 Hz), 3.16 (m, 1H), 1.23 (d, 6H, *J* = 6.6 Hz); ¹³C{¹H} NMR (CDCl₃, 100 MHz) δ 188.8, 149.3,
26 140.4, 139.6, 139.3, 136.6, 135.6, 129.4, 125.9, 121.8, 120.6, 30.8, 23.2; HRMS (ESI+) *m/z*: [M + H]⁺ Calcd for C₁₄H₁₄BrO 277.0223; Found
27 277.0226.

28
29
30
31
32
33
34
35 *(E)-5-Bromo-1-(2-methylpropylidene)-1H-inden-3-yl)methanol (21)*. To a solution of aldehyde **9** (98.2 mg, 0.354 mmol) in EtOH (6.00
36 mL) was added a solution of CeCl₃·7H₂O (186 mg, 0.499 mmol), NaBH₄ (16.0 mg, 0.423 mmol) in EtOH (8.00 mL) dropwise at 0 °C. After
37 being stirred for 1 h at the same temperature, the reaction mixture was quenched with 1N HCl and then concentrated in vacuo. The residue
38 was extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by
39 flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 6 to 1 : 4) to afford 92.7 mg (94%) of alcohol **21** as yellow solid: FT-IR
40 (thin film, neat) ν_{\max} 3348, 2960, 2927, 2868, 1712, 1648, 1596, 1558, 1446, 1416, 1385, 1362, 1323 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ
41 7.46 (d, 1H, *J* = 1.7 Hz), 7.42 (d, 1H, *J* = 8.0 Hz), 7.32 (dd, 1H, *J* = 8.0, 1.7 Hz), 6.78 (m, 1H), 6.42 (dd, 1H, *J* = 10.0, 0.3 Hz), 4.72 (d, 2H,
42 *J* = 1.8 Hz), 3.02 (m, 1H), 1.96 (s, 1H), 1.16 (d, 6H, 6.6 Hz); ¹³C{¹H} NMR (CDCl₃, 100 MHz) δ 143.4, 142.8, 140.5, 136.4, 136.3, 128.0,
43 122.6, 122.4, 120.8, 120.4, 59.7, 29.9, 23.3; HRMS (FAB+) *m/z*: [M]⁺ Calcd for C₁₄H₁₅BrO 278.0306; Found 278.0300.

44
45
46
47
48
49
50 *Regioisomer of anmindenol A (7)*. To a solution of alcohol **21** (31.0 mg, 0.111 mmol) in THF (3.00 mL) was added a solution of Pd(PPh₃)₄
51 (19.0 mg, 16.4 μ mol) in THF (2.00 mL) and Me₂Zn (278 μ L of a 1.2 M solution in toluene) at ambient temperature. After being refluxed for
52 2 h, the reaction mixture was quenched with saturated NaHCO₃ and then extracted with EtOAc. The combined organic layers were dried
53 over MgSO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 4)
54
55

1
2
3 to afford 23.6 mg (99%) of **7** as a yellow oil: FT-IR (thin film, neat) ν_{\max} 3370, 2961, 2867, 1708, 1648, 1610, 1462 cm^{-1} ; ^1H NMR (CDCl_3 ,
4 400 MHz) δ 7.47 (d, 1H, $J = 7.6$ Hz), 7.15 (m, 1H), 7.03 (d, 1H, $J = 7.6$ Hz), 6.74 (m, 1H), 6.36 (d, 1H, $J = 9.8$ Hz), 4.76 (dd, 2H, $J = 5.8$,
5 1.0 Hz), 3.04 (m, 1H), 2.39 (s, 3H), 1.16 (d, 6H, $J = 6.6$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 144.1, 141.2, 138.5, 136.9, 136.9, 135.2,
6 126.2, 121.6, 119.9, 118.9, 60.1, 29.8, 23.5, 21.8; HRMS (FAB+) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{15}\text{H}_{18}\text{O}$ 214.1358; Found 214.1346.
7
8

9
10 (*E*)-6-Bromo-1-ethylidene-1H-indene-3-carbaldehyde (**22**). To a solution of the acetaldehyde (35.4 μL , 0.631 mmol) in THF (9.46 mL)
11 was added Bu_2BOTf (631 μL of a 1.0 M solution in CH_2Cl_2) at ambient temperature. To a reaction mixture was immediately added a solution
12 of enamine **10** (158 mg, 0.631 mmol) in THF (3.16 mL) via cannula. After being stirred for 3 h at the same temperature, the reaction mixture
13 was quenched with H_2O and then extracted with EtOAc. The combined organic layers were dried over Na_2SO_4 and concentrated in vacuo.
14 The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 10) to afford 80.4 mg (57% yield, $E : Z =$
15 4.5 : 1) of **22** as yellow solid: FT-IR (thin film, neat) ν_{\max} 3402, 3063, 2965, 2927, 2817, 2718, 1714, 1678, 1641, 1597, 1559, 1538, 1452,
16 1416, 1389 cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz) δ 10.12 (s, 1H), 7.94 (d, 1H, $J = 8.1$ Hz), 7.70 (d, 1H, $J = 1.7$ Hz), 7.53 (s, 1H), 7.43 (dd, 1H,
17 $J = 8.1, 1.8$ Hz), 7.06 (q, 1H, $J = 7.5$ Hz), 2.31 (d, 3H, $J = 7.5$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 188.9, 140.7, 139.6, 138.6, 138.3,
18 138.0, 136.4, 130.6, 124.0, 122.6, 120.8, 17.0; HRMS (ESI-) m/z : $[\text{M} - \text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_8\text{BrO}$ 246.9764; Found 246.9766.
19
20
21
22
23

24
25 (*E*)-5-Bromo-1-ethylidene-1H-indene-3-carbaldehyde (**23**). Enamine **11** (114 mg, 0.456 mmol) was reacted under the condition described
26 above for **22**. The crude product was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 7) to afford 76.6 mg
27 (68% yield, $E : Z = 4 : 1$) of **23** as yellow solid: FT-IR (thin film, neat) ν_{\max} 3401, 3061, 2963, 2929, 2872, 2825, 2718, 1881, 1716, 1679,
28 1641, 1596, 1568, 1541, 1450, 1419, 1379, 1305 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 10.11 (s, 1H), 8.24 (d, 1H, $J = 0.9$ Hz), 7.57 (s, 1H),
29 7.44 (d, 1H, $J = 8.1$ Hz), 7.40 (dd, 1H, $J = 8.1, 1.3$ Hz), 7.08 (q, 1H, $J = 7.5$ Hz), 2.31 (d, 3H, $J = 7.5$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz)
30 δ 188.8, 140.3, 139.8, 139.2, 139.2, 137.8, 135.4, 129.4, 125.9, 121.7, 120.5, 17.0; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_{10}\text{BrO}$
31 248.9910; Found 248.9913.
32
33
34
35

36
37 (*E*)-6-Bromo-1-propylidene-1H-indene-3-carbaldehyde (**24**). To a solution of the propionaldehyde (45.7 μL , 0.636 mmol) in THF (9.50
38 mL) was added Bu_2BOTf (636 μL of a 1.0 M solution in CH_2Cl_2) at ambient temperature. To a reaction mixture was immediately added a
39 solution of enamine **10** (159 mg, 0.636 mmol) in THF (3.20 mL) via cannula. After being stirred for 3 h at the same temperature, the reaction
40 mixture was quenched with H_2O and then extracted with EtOAc. The combined organic layers were dried over Na_2SO_4 and concentrated in
41 vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 7) to afford 69.9 mg (42% yield, $E :$
42 $Z = 4.5 : 1$) of **24** as yellow solid: FT-IR (thin film, neat) ν_{\max} 2967, 2932, 2873, 2814, 2716, 1715, 1678, 1638, 1595, 1538, 1450, 1415,
43 1391 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 10.12 (s, 1H), 7.94 (d, 1H, $J = 8.2$ Hz), 7.74 (d, 1H, $J = 1.6$ Hz), 7.53 (s, 1H), 7.44 (dd, 1H, $J =$
44 8.2, 1.7 Hz), 7.01 (t, 1H, $J = 8.1$ Hz), 2.69 (quintet, 2H, $J = 7.6$ Hz), 1.24 (t, 3H, $J = 7.5$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 189.0,
45 144.6, 140.7, 138.7, 138.6, 138.1, 136.4, 130.6, 124.0, 122.7, 120.8, 24.6, 14.1; HRMS (ESI-) m/z : $[\text{M} - \text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{10}\text{BrO}$ 260.9921;
46 Found 260.9927.
47
48
49
50
51

52
53 (*E*)-5-Bromo-1-propylidene-1H-indene-3-carbaldehyde (**25**). Enamine **11** (103 mg, 0.412 mmol) was reacted under the condition
54 described above for **24**. The crude product was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 4) to afford
55
56
57

38.2 mg (35% yield, $E : Z = 4 : 1$) of **25** as yellow solid: FT-IR (thin film, neat) ν_{\max} 3062, 2964, 2930, 2873, 2716, 1716, 1678, 1636, 1596, 1564, 1541, 1447, 1421, 1383, 1306 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 10.12 (s, 1H), 8.25 (d, 1H, $J = 1.4$ Hz), 7.57 (s, 1H), 7.47 (d, 1H, $J = 8.1$ Hz), 7.41 (dd, 1H, $J = 8.1, 1.5$ Hz), 7.02 (t, 1H, $J = 8.1$ Hz), 2.70 (quintet, 2H, $J = 7.7$ Hz), 1.25 (t, 1H, $J = 7.5$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 188.8, 144.3, 140.4, 139.4, 139.3, 138.3, 135.5, 129.5, 125.9, 121.8, 120.6, 24.7, 14.1; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{12}\text{BrO}$ 263.0066; Found 263.0051.

(*E*)-6-Bromo-1-(2,2-dimethylpropylidene)-1H-indene-3-carbaldehyde (**26**). To a solution of the pivalaldehyde (31.0 μL , 0.281 mmol) in THF (4.22 mL) was added Bu_2BOTf (281 μL of a 1.0 M solution in CH_2Cl_2) at ambient temperature. To a reaction mixture was immediately added a solution of enamine **10** (70.3 mg, 0.281 mmol) in THF (1.40 mL) via cannula. After being stirred for 3 h at the same temperature, the reaction mixture was quenched with H_2O and then extracted with EtOAc. The combined organic layers were dried over Na_2SO_4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (EtOAc / *n*-hexane = 1 : 7) to afford 32.0 mg (39%) of **26** as a yellow oil: ^1H NMR (CDCl_3 , 500 MHz) δ 10.13 (s, 1H), 7.95 (d, 1H, $J = 8.1$), 7.74 (s, 1H), 7.72 (s, 1H), 7.44 (d, 1H, $J = 8.1$ Hz), 7.06 (s, 1H), 1.39 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR ($\text{DMSO-}d_6$, 125 MHz) δ 190.4, 155.7, 140.7, 140.3, 140.0, 134.7, 134.1, 129.9, 123.1, 123.0, 119.8, 36.5, 30.6; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{16}\text{BrO}$ 291.0379; Found 291.0383.

(*E*)-5-Bromo-1-(2,2-dimethylpropylidene)-1H-indene-3-carbaldehyde (**27**). Enamine **11** (107 mg, 0.428 mmol) was reacted under the condition described above for **26**. The crude product was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 8) to afford 71.1 mg (57%) of **27** as yellow solid: ^1H NMR (CDCl_3 , 500 MHz) δ 10.12 (s, 1H), 8.25 (s, 1H), 7.77 (s, 1H), 7.47 (d, 1H, $J = 8.1$ Hz), 7.41 (d, 1H, $J = 8.1$ Hz), 7.07 (s, 1H), 1.40 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR ($\text{DMSO-}d_6$, 125 MHz) δ 190.2, 154.9, 141.3, 139.6, 137.6, 137.1, 134.3, 128.7, 124.1, 121.5, 120.2, 36.3, 30.6; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{16}\text{BrO}$ 291.0379; Found 291.0391.

General procedure for preparation of alcohols 28-33: To a solution of the starting aldehyde in EtOH was added a solution of $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (1.0 equiv), NaBH_4 (1.0 equiv) in EtOH dropwise at 0 $^\circ\text{C}$. After being stirred for 1 h at the same temperature, the reaction mixture was quenched with 1N HCl and then concentrated in vacuo. The residue was extracted with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel.

(*E*)-(6-Bromo-1-ethylidene-1H-inden-3-yl)methanol (**28**). Aldehyde **22** (90.7 mg, 0.364 mmol) afforded 76.2 mg (83%) of **28** as yellow solid via the above general procedure. Compound **28** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 3) : FT-IR (thin film, neat) ν_{\max} 3361, 2912, 2866, 1708, 1650, 1596, 1447, 1416, 1373, 1317 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 7.67 (d, 1H, $J = 1.1$ Hz), 7.36 (dd, 1H, $J = 8.0, 1.3$ Hz), 7.20 (d, 1H, $J = 8.0$ Hz), 6.78 (s, 1H), 6.66 (q, 1H, $J = 7.3$ Hz), 4.75 (d, 2H, $J = 2.4$ Hz), 2.18 (d, 3H, $J = 7.3$ Hz), 1.65 (t, 1H, $J = 5.3$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 143.8, 139.7, 139.5, 139.4, 129.6, 128.7, 122.4, 121.4, 120.5, 119.6, 59.9, 16.1; HRMS (ESI-) m/z : $[\text{M} - \text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_{10}\text{BrO}$ 248.9920; Found 248.9924.

(*E*)-(5-Bromo-1-ethylidene-1H-inden-3-yl)methanol (**29**). Aldehyde **23** (212 mg, 0.851 mmol) afforded 186 mg (87%) of **29** as yellow solid via the above general procedure. Compound **29** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 3) : FT-IR (thin film, neat) ν_{\max} 3315, 3070, 2913, 2863, 1871, 1711, 1650, 1596, 1558, 1445, 1417, 1368, 1315 cm^{-1} ; ^1H NMR (CDCl_3 , 500

MHz) δ 7.48 (s, 1H), 7.42 (d, 1H, J = 8.0 Hz), 7.33 (d, 1H, J = 8.0 Hz), 6.82 (s, 1H), 6.67 (q, 1H, J = 7.3 Hz), 4.75 (s, 2H), 2.17 (d, 3H, J = 7.3 Hz), 1.62 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 143.4, 142.8, 139.4, 136.2, 128.5, 128.1, 122.5, 122.3, 120.8, 120.3, 59.8, 16.1.

(*E*)-(6-Bromo-1-propylidene-1H-inden-3-yl)methanol (**30**). Aldehyde **24** (52.4 mg, 0.199 mmol) afforded 40.0 mg (76%) of **30** as yellow solid via the above general procedure. Compound **30** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 4) : FT-IR (thin film, neat) ν_{max} 3350, 2966, 2931, 2871, 1707, 1648, 1596, 1557, 1449, 1415, 1376, 1341, 1316 cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz) δ 7.69 (d, 1H, J = 1.8 Hz), 7.37 (dd, 1H, J = 8.0, 1.7 Hz), 7.20 (d, 1H, J = 8.0 Hz), 6.76 (m, 1H), 6.60 (t, 1H, J = 7.9 Hz), 4.76 (d, 2H, J = 4.0 Hz), 2.57 (quintet, 2H, J = 7.6 Hz), 1.62 (t, 1H, J = 5.9 Hz), 1.18 (t, 3H, J = 7.5 Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 143.9, 139.8, 139.6, 138.0, 135.6, 129.7, 122.6, 121.6, 120.5, 119.6, 59.9, 23.8, 14.4; HRMS (ESI-) m/z : $[\text{M} - \text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{12}\text{BrO}$ 263.0077; Found 263.0076.

(*E*)-(5-Bromo-1-propylidene-1H-inden-3-yl)methanol (**31**). Aldehyde **25** (50.7 mg, 0.193 mmol) afforded 42.0 mg (82%) of **31** as yellow solid via the above general procedure. Compound **31** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 5) : FT-IR (thin film, neat) ν_{max} 3347, 3327, 2966, 2931, 2872, 1711, 1648, 1596, 1559, 1446, 1416, 1378, 1324 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 7.48 (d, 1H, J = 1.5 Hz), 7.43 (d, 1H, J = 8.0 Hz), 7.34 (dd, 1H, J = 8.0, 1.6 Hz), 6.80 (s, 1H), 6.61 (t, 1H, J = 7.9 Hz), 4.75 (d, 2H, J = 4.2 Hz), 2.57 (quintet, 2H, J = 7.6 Hz), 1.61 (t, 1H, J = 5.1 Hz), 1.18 (t, 3H, J = 7.5 Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 143.4, 142.8, 137.9, 136.3, 135.4, 128.1, 122.5, 122.5, 120.8, 120.4, 59.8, 23.8, 14.4.

(*E*)-(6-Bromo-1-(2,2-dimethylpropylidene)-1H-inden-3-yl)methanol (**32**). Aldehyde **26** (18.1 mg, 0.062 mmol) afforded 15.6 mg (86%) of **32** as yellow solid via the above general procedure. Compound **32** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 5) : FT-IR (thin film, neat) ν_{max} 3305, 2957, 2929, 2903, 2866, 1636, 1587, 1556, 1451, 1415, 1396, 1363, 1346, 1317 cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz) δ 7.69 (d, 1H, J = 1.7 Hz), 7.36 (dd, 1H, J = 8.0, 1.7 Hz), 7.19 (d, 1H, J = 8.0 Hz), 6.93 (m, 1H), 6.66 (s, 1H), 4.75 (s, 1H), 1.73 (s, 1H), 1.33 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 144.4, 144.2, 141.1, 138.3, 135.1, 129.6, 122.3, 122.3, 120.3, 119.6, 59.9, 35.4, 31.4.

(*E*)-(5-Bromo-1-(2,2-dimethylpropylidene)-1H-inden-3-yl)methanol (**33**). Aldehyde **27** (32.5 mg, 0.111 mmol) afforded 26.4 mg (81%) of **33** as yellow solid via the above general procedure. Compound **33** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 4) : FT-IR (thin film, neat) ν_{max} 3304, 2957, 2930, 2903, 2865, 1864, 1713, 1636, 1594, 1558, 1447, 1417, 1362, 1316 cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz) δ 7.47 (d, 1H, J = 1.7 Hz), 7.43 (d, 1H, J = 8.1 Hz), 7.33 (dd, 1H, J = 8.1, 1.7 Hz), 6.97 (m, 1H), 6.67 (s, 1H), 4.74 (s, 2H), 1.71 (s, 1H), 1.33 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 144.0, 144.0, 141.4, 137.8, 135.1, 128.0, 123.2, 122.3, 120.7, 120.1, 59.8, 35.4, 31.5.

General procedure for preparation of 34-39: To a solution of the starting alcohol in THF was added a solution of $\text{Pd}(\text{PPh}_3)_4$ (0.3 equiv) in THF and Me_2Zn (3.0 equiv) at ambient temperature. After being refluxed for 2 h, the reaction mixture was quenched with saturated NaHCO_3 and then extracted with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel.

1
2
3 *(E)*-(1-Ethylidene-6-methyl-1*H*-inden-3-yl)methanol (**34**). Alcohol **28** (76.2 mg, 0.303 mmol) afforded 41.2 mg (73%) of **34** as yellow
4 solid via the above general procedure. Compound **34** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 4) :
5 FT-IR (thin film, neat) ν_{\max} 3303, 3007, 2973, 2915, 2856, 1651, 1610, 1590, 1564, 1439, 1370, 1321 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ
6 7.39 (s, 1H), 7.21 (d, 1H, $J = 7.6$ Hz), 7.06 (d, 1H, $J = 7.5$ Hz), 6.72 (s, 1H), 6.63 (q, 1H, $J = 7.3$ Hz), 4.76 (d, 2H, $J = 3.9$ Hz), 2.40 (s, 3H),
7 2.16 (d, 3H, $J = 7.3$ Hz), 1.57 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 144.3, 140.3, 138.4, 137.9, 135.2, 127.7, 126.4, 120.2, 119.9,
8 118.8, 60.1, 21.8, 15.9; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{15}\text{O}$ 187.1117; Found 187.1111.

9
10
11
12
13 *(E)*-(1-Ethylidene-5-methyl-1*H*-inden-3-yl)methanol (**35**). Alcohol **29** (186.2 mg, 0.741 mmol) afforded 118 mg (85%) of **35** as yellow
14 solid via the above general procedure. Compound **35** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 4) :
15 FT-IR (thin film, neat) ν_{\max} 3379, 3047, 2978, 2930, 2868, 1708, 1650, 1610, 1576, 1450, 1373, 1320 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ
16 7.45 (d, 1H, $J = 7.7$ Hz), 7.16 (s, 1H), 7.03 (d, 1H, $J = 7.6$ Hz), 6.77 (s, 1H), 6.60 (q, 1H, $J = 7.3$ Hz), 4.76 (d, 2H, $J = 2.8$), 2.40 (s, 3H), 2.16
17 (d, 3H, $J = 7.4$ Hz), 1.59 (t, 1H, $J = 5.3$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 144.0, 141.1, 139.9, 136.7, 134.9, 126.2, 126.1, 121.2,
18 119.8, 118.7, 60.0, 21.7, 15.8; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{15}\text{O}$ 187.1117; Found 187.1112.

19
20
21
22
23 *(E)*-(6-Methyl-1-propylidene-1*H*-inden-3-yl)methanol (**36**). Alcohol **30** (65.5 mg, 0.247 mmol) afforded 43.2 mg (87%) of **36** as yellow
24 solid via the above general procedure. Compound **36** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 5) :
25 FT-IR (thin film, neat) ν_{\max} 3322, 2966, 2931, 2873, 1706, 1648, 1608, 1456, 1377, 1324 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 7.41 (s, 1H),
26 7.21 (d, 1H, $J = 7.6$ Hz), 7.06 (d, 1H, $J = 7.6$ Hz), 6.70 (s, 1H), 6.57 (t, 1H, $J = 7.8$ Hz), 4.76 (s, 2H), 2.56 (quintet, 2H, $J = 7.6$ Hz), 2.40 (s,
27 3H), 1.58 (s, 1H), 1.17 (t, 3H, $J = 7.5$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 144.4, 138.7, 138.5, 138.0, 135.2, 133.4, 127.7, 120.4, 120.0,
28 118.8, 60.1, 23.6, 21.8, 14.5; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{17}\text{O}$ 201.1274; Found 201.1266.

29
30
31
32
33 *(E)*-(5-Methyl-1-propylidene-1*H*-inden-3-yl)methanol (**37**). Alcohol **31** (48.0 mg, 0.181 mmol) afforded 34.0 mg (94%) of **37** as a yellow
34 oil via the above general procedure. Compound **37** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane = 1 : 5) :
35 FT-IR (thin film, neat) ν_{\max} 3342, 2966, 2930, 2872, 2732, 1709, 1648, 1611, 1570, 1458, 1378, 1326 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ
36 7.47 (d, 1H, $J = 7.6$ Hz), 7.16 (s, 1H), 7.03 (d, 1H, $J = 7.6$ Hz), 6.74 (s, 1H), 6.54 (t, 1H, $J = 7.8$ Hz), 4.76 (d, 2H, $J = 5.0$ Hz), 2.56 (quintet,
37 2H, $J = 7.6$ Hz), 2.40 (s, 3H), 1.58 (t, 1H, $J = 5.6$ Hz), 1.17 (t, 3H, $J = 7.5$ Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) δ 144.2, 141.2, 138.6,
38 136.9, 135.1, 133.3, 126.2, 121.5, 119.9, 118.9, 60.1, 23.6, 21.8, 14.6; HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{17}\text{O}$ 201.1274; Found
39 201.1265.

40
41
42
43
44
45 *(E)*-(1-(2,2-Dimethylpropylidene)-6-methyl-1*H*-inden-3-yl)methanol (**38**). Alcohol **32** (10.3 mg, 0.035 mmol) afforded 7.3 mg (96%) of
46 **38** as yellow solid via the above general procedure. Compound **38** was purified by flash column chromatography on silica gel (EtOAc : *n*-
47 hexane = 1 : 5) : FT-IR (thin film, neat) ν_{\max} 3313, 2956, 2926, 2864, 1715, 1634, 1561, 1461, 1394, 1376, 1363, 1345, 1322 cm^{-1} ; ^1H NMR
48 (CDCl_3 , 400 MHz) δ 7.40 (s, 1H), 7.21 (d, 1H, $J = 7.6$ Hz), 7.06 (d, 1H, $J = 7.6$ Hz), 6.87 (m, 1H), 6.64 (s, 1H), 4.76 (s, 2H), 2.41 (s, 3H),
49 1.33 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) δ 145.0, 142.1, 139.5, 137.1, 135.9, 135.2, 127.6, 121.2, 119.7, 118.7, 60.2, 35.1, 31.6, 21.8;
50 HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{21}\text{O}$ 229.1587; Found 229.1583.
51
52
53
54
55
56
57
58
59
60

1
2
3 *(E)*-(1-(2,2-Dimethylpropylidene)-5-methyl-1H-inden-3-yl)methanol (**39**). Alcohol **33** (6.0 mg, 0.020 mmol) afforded 4.2 mg (97%) of **39**
4 as a yellow oil via the above general procedure. Compound **39** was purified by flash column chromatography on silica gel (EtOAc : *n*-hexane
5 = 1 : 5) : FT-IR (thin film, neat) ν_{\max} 3312, 2957, 2927, 2904, 2865, 1636, 1611, 1595, 1559, 1461, 1396, 1377, 1363, 1322 cm^{-1} ; ^1H NMR
6 (CDCl₃, 400 MHz) δ 7.46 (d, 1H, $J = 7.7$ Hz), 7.16 (m, 1H), 7.04 (m, 1H), 6.92 (d, 1H, $J = 1.0$ Hz), 6.62 (s, 1H), 4.77 (s, 2H), 2.40 (s, 3H),
7 1.65 (s, 1H), 1.33 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl₃, 100 MHz) δ 144.8, 142.0, 139.8, 136.8, 136.6, 135.8, 126.2, 122.2, 119.7, 118.6, 60.1,
8 35.1, 31.6, 21.7; HRMS (ESI+) m/z : [M + H]⁺ Calcd for C₁₆H₂₁O 229.1587; Found 229.1581.
9
10
11
12

13 **Molecular Docking Simulations**

14
15
16 The 3D ligand structure was prepared and minimized by MM2 using Chem 3D Pro 12.0 software. The structure of iNOS was downloaded
17 from the RCSB protein data bank (PDB ID: 1M8D). Chain B and all non-standard residues of the protein were removed by using UCSF
18 Chimera 1.11.¹⁸ Resulting ligand and protein files were processed in accordance with the AutoDock protocol for docking simulations.¹⁹
19 Molecular docking analysis were performed using AutoDock Tools 1.5.6. and AutoDock 4.2.²⁰ and the visual investigation and hydrogen
20 bonding analysis were accomplished using UCSF Chimera 1.11.
21
22
23

24 **Nitric Oxide Detection**

25
26
27 RAW 264.7 cells (American Type Culture Collection, Manassas, VA, USA) were plated at a density of 1.5×10^5 cells/cm² on 48 well
28 plates. Cells were stabilized for 24 h in Dulbecco's Modified Eagle Medium with high glucose (Gibco BRL, Grand Island, NY, USA)
29 containing 10% Fetal Bovine Serum (Gibco BRL) at 37 °C in a humidified incubator with 5% CO₂ followed by media replacement. Cells
30 were treated with 1 $\mu\text{g}/\text{mL}$ LPS (Invivogen, San Diego, California, USA) for 24 h in the presence or absence of chemical compounds in
31 concentrations ranging from 6.25 to 100 μM (2-fold serial dilution). NO was measured from culture supernatant using a Griess reagent
32 (Promega, Madison, Wisconsin, USA) according to the manufacturer's instruction. Absorbance at 535 nm was measured using a microplate
33 reader (Bio-Tek, Winooski, VT, USA).
34
35
36
37
38
39
40
41

42 **ASSOCIATED CONTENT**

43 **Supporting Information**

44
45 The Supporting Information is available free of charge on the ACS Publications website at DOI:

46
47
48
49 Copies of the ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra for all compounds, natural and synthetic compound comparison tables and computational docking
50 analysis. (PDF)
51

52 **ACKNOWLEDGEMENTS**

53
54
55
56 This research was supported by a grant from the Health Fellowship Foundation.
57
58
59
60

REFERENCES

- (1) For selected examples of biologically active benzofulvenes, see: (a) Kumar, V.; Alexander, M. D.; Bell, M. R.; Eissenstat, M. A.; Casiano, F. M.; Chippari, S. M.; Haycock, D. A.; Luttinger, D. A.; Kuster, J. E.; Miller, M. S.; Stevenson, J. I.; Ward, S. J. Morpholinoalkylindenes as Antinociceptive Agents: Novel Cannabinoid Receptor Agonists. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 381–386. (b) Böhme, T. M.; Keim, C.; Dannhardt, G.; Mutschler, E.; Lambrecht, G. Design and Pharmacology of Quinuclidine Derivatives as M₂-Selective Muscarinic Receptor Ligands. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1241–1243. (c) Alcalde, E.; Mesquida, N.; Frigola, J.; López-Pérez, S.; Mercè, R. Indene-based scaffolds. Design and synthesis of novel serotonin 5-HT₆ receptor ligands. *Org. Biomol. Chem.* **2008**, *6*, 3795–3810. (d) Felts, A. S.; Siegel, B. S.; Young, S. M.; Moth, C. W.; Lybrand, T. P.; Dannenberg, A. J.; Marnett, L. J.; Subbaramaiah, K. Sulindac Derivatives That Activate the Peroxisome Proliferator-activated Receptor γ but Lack Cyclooxygenase Inhibition. *J. Med. Chem.* **2008**, *51*, 4911–4919. (e) Walters, M. J.; Blobaum, A. L.; Kingsley, P. J.; Felfts, A. S.; Sulikowski, G. A.; Marnett, L. J. The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3271–3274. (f) Liedtke, A. J.; Crews, B. C.; Daniel, C. M.; Blobaum, A. L.; Kingsley, P. J.; Ghebreselasie, K.; Marnett, L. J. Cyclooxygenase-1-Selective Inhibitors Based on the (*E*)-2'-Desmethyl-sulindac Sulfide Scaffold. *J. Med. Chem.* **2012**, *55*, 2287–2300. (g) Seltzman, H. H.; Shiner, C.; Hirt, E. E.; Gilliam, A. F.; Thomas, B. F.; Maitra, R.; Snyder, R.; Black, S. L.; Patel, P. R.; Mulpuri, Y.; Spigelman, I. Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. *J. Med. Chem.* **2016**, *59*, 7525–7543.
- (2) For selected examples of benzofulvenes applied to materials science, see: (a) Lash, T. D.; Colby, D. A.; Idate, A. S.; Davis, R. N. Fulvene Dialdehyde Strategy for *adj*-Dicarbaporphyrinoid Synthesis: Preparation of a 22-Carbaazulporphyrin. *J. Am. Chem. Soc.* **2007**, *129*, 13800–13801. (b) Cappelli, A.; Galeazzi, S.; Giuliani, G.; Anzini, M.; Aggravi, M.; Donati, A.; Zetta, L.; Boccia, A. C.; Mendichi, R.; Giorgi, G.; Paccagnini, E.; Vomero, S. Anionic Polymerization of a Benzofulvene Monomer Leading to a Thermoreversible π -Stacked Polymer. Studies in Macromolecular and Aggregate Structure. *Macromolecules* **2008**, *41*, 2324–2334. (c) Kosaka, Y.; Kitazawa, K.; Inomata, S.; Ishizone, T. Living Anionic Polymerization of Benzofulvene: Highly Reactive Fixed Transoid 1,3-Diene. *ACS Macro Lett.* **2013**, *2*, 164–167. (d) Fischer, M.; Oswald, T.; Ebert, H.; Schmidtman, M.; Beckhaus, R. Expanding the Scope: Monopentafulvene and -Benzofulvene Complexes of Zirconium and Hafnium. *Organometallics* **2018**, *37*, 415–421. (e) Paolino, M.; Grisci, G.; Reale, A.; Razzano, V.; Giuliani, G.; Donati, A.; Mendichi, R.; Piovani, D.; Boccia, A. C.; Grillo, A.; Giorgi, G.; Cappelli, A. Structural Manipulation of the Conjugated Phenyl Moiety in 3-Phenylbenzofulvene Monomers: Effects on Spontaneous Polymerization. *Polymers* **2018**, *10*, 752–771.
- (3) (a) Lee, J.; Kim, H.; Lee, T. G.; Yang, I.; Won, D. H.; Choi, H.; Nam, S.-J.; Kang, H. Anmidenols A and B, Inducible Nitric Oxide Synthase Inhibitors from a Marine-Derived *Streptomyces* sp. *J. Nat. Prod.* **2014**, *77*, 1528–1531. (b) Shen, Q.; Xu, X.; Liu, C.; Zhao, W.; Xiang, N.; Chen, Y.; Miao, M.; Liu, Z.; Yang, G. Two new sesquiterpenes from the leaves of *Nicotiana tabacum* and their anti-tobacco mosaic virus activities. *Nat. Prod. Res.* **2016**, *30*, 2545–2550. (c) Farooq, U.; Naz, S.; Zehra, B.; Khan, A.; Ali, S. A.; Ahmed, A.; Sarwar, R.; Bukhari, S. M.; Rauf, A.; Ahmad, I.; Mabkhot, Y. N. Isolation and characterization of three new anti-proliferative Sesquiterpenes from *Polygonum barbatum* and their mechanism via apoptotic pathway. *BMC Cancer* **2017**, *17*, 694–706.
- (4) (a) Lu, W.; Zhu, Q.; Yan, C.-g. Kf-Al₂O₃ Induced Condensations of Indene with Aromatic Aldehydes. *Synth. Commun.* **1997**, *27*, 3985–3990. (b) Donslund, B. S.; Nielsen, R. P.; Mønsted, S. M. N.; Jørgensen, K. A. Benzofulvenes in Trienamine Catalysis: Stereoselective Spiroindene

- 1
2
3 Synthesis. *Angew. Chem., Int. Ed.* **2016**, *55*, 11124–11128. (c) Yi, R.; Chen, J.; Wang, X.; Liang, Z. Xu, X. A Rapid and Highly Efficient Method
4 for the Synthesis of Benzofulvenes via CsOH-Catalyzed Condensation of Indene and Aldehydes. *Eur. J. Org. Chem.* **2018**, *2018*, 1347–1351.
- 5
6 (5) Marcuzzi, F.; Azzena, U.; Melloni, G. Vinyl Cations in Organic Synthesis. Part 2. A Novel Synthesis of Methylene-1*H*-indenes (Benzofulvenes)
7 by Cyclisation of Phenyl-substituted But-1-en-3-yne. *J. Chem. Soc., Perkin Trans. 1* **1993**, 2957–2960.
- 8
9 (6) (a) Shibata, T.; Ueno, Y.; Kanda, K. Cationic Au(I)-Catalyzed Cycloisomerization of Aromatic Enynes for the Synthesis of Substituted
10 Naphthalenes. *Synlett* **2006**, *3*, 411–414. (b) Aziz, J.; Frison, G.; Menez, P. L.; Brion, J.-D.; Hamze, A. Alami, M. Gold versus Palladium: A
11 Regioselective Cycloisomerization of Aromatic Enynes. *Adv. Synth. Catal.* **2013**, *355*, 3425–3436.
- 12
13 (7) Somai Magar, K. B.; Lee, Y. R. Synthesis of Diverse Indene Derivatives from 1-Diazonaphthalen-2(1*H*)-ones via Thermal Cascade Reactions.
14 *Org. Lett.* **2013**, *15*, 4288–4291.
- 15
16 (8) (a) Davis, R. N.; Lash, T. D. Preparation of stable fulvene and difulvene aldehydes from benzaldehydes and an indene-derived enamine: formation
17 of novel indene-fused benzodiazepines and attempted syntheses of di- and tricarbaporphyrinoid systems. *Tetrahedron* **2009**, *65*, 9935–9943. (b) Jain,
18 P.; Ferrence, G. M.; Lash, T. D. Preparation of Furan and Thiophene-Derived Fulvene Dialdehydes: Synthesis and Structural Characterization of a
19 22-Oxa-21-carbaporphyrin and a Related Palladium(II) Organometallic Complex. *J. Org. Chem.* **2010**, *75*, 6563–6573. (c) Lash, T. D.; Lammer, A.
20 D.; Idate, A. S.; Colby, D. A.; White, K. Preparation of Azulene-Derived Fulvenedialdehydes and Their Application to the Synthesis of Stable *adj*-
21 Dicarbaporphyrinoids. *J. Org. Chem.* **2012**, *77*, 2368–2381. (d) Lash, T. D.; Fosu, S. C.; Smolczyk, T. J.; AbuSalim, D. I. Synthesis of Expanded
22 Porphyrinoids with Azulene and Indene Subunits and an *opp*-Dioxadicalcarbaporphyrin from Fulvene Carbinols and a Dioxacarbatripyrrin. *J. Org.*
23 *Chem.* **2018**, *83*, 12619–12631.
- 24
25 (9) (a) Luche, J.-L. Lanthanides in Organic Chemistry. 1. Selective 1,2 Reductions of Conjugated Ketones. *J. Am. Chem. Soc.* **1978**, *100*, 2226–2227.
26 (b) Luche, J.-L.; Rodriguez-Hahn, L.; Crabbé, P. Reduction of Natural Enones in the Presence of Cerium Trichloride. *J. Chem. Soc., Chem. Commun.*
27 **1978**, 601–602. (c) Gemal, A. L.; Luche, J.-L. Lanthanoids in Organic Synthesis. 6. The Reduction of α -Enones by Sodium Borohydride in the
28 Presence of Lanthanoid Chlorides: Synthetic and Mechanistic Aspects. *J. Am. Chem. Soc.* **1981**, *103*, 5454–5459.
- 29
30 (10) (a) Negishi, E.-i.; King, A. O.; Okukado, N. Selective Carbon-Carbon Bond Formation via Transition Metal Catalysis. 3. A Highly Selective
31 Synthesis of Unsymmetrical Biaryls and Diarylmethanes by the Nickel- or Palladium-Catalyzed Reaction of Aryl- and Benzylzinc Derivatives with
32 Aryl Halides. *J. Org. Chem.* **1977**, *42*, 1821–1823. (b) Herbert, J. M. Negishi-type coupling of bromoarenes with dimethylzinc. *Tetrahedron Lett.*
33 **2004**, *45*, 817–819. (c) Liu, Q.; Yue, G.; Wu, N.; Lin, G.; Li, Y.; Quan, J.; Li, C.-c.; Wang, G.; Yang, Z. Total Synthesis of (\pm)-Pentalenolactone A
34 Methyl Ester. *Angew. Chem., Int. Ed.* **2012**, *51*, 12072–12076.
- 35
36 (11) Adameczyk, M.; Watt, D. S. Synthesis of Biological Markers in Fossil Fuels. 2. Synthesis and ^{13}C NMR Studies of Substituted Indans and
37 Tetralins. *J. Org. Chem.* **1984**, *49*, 4226–4237.
- 38
39 (12) Arnold, Z. Synthetic Reactions of Dimethylformamide. XXII. Formation and Preparation of Formyl Derivatives of Indene. *Collect. Czech.*
40 *Chem. Commun.* **1965**, *30*, 2783–2792.
- 41
42 (13) (a) Maehr, H.; Smallheer, J.; Blount, J. F.; Todaro, L. J. *N*-[(4-Nitro-1*H*-inden-1-ylidene)methyl]dialkylamines by an Unexpected Reaction. *J.*
43 *Org. Chem.* **1981**, *46*, 5019–5021. (b) Quirion, J.-C. Product Subclass 19: 1,2,3,4-Tetrahydropyridines and Derivatives. In *Science of Synthesis:*
44 *Houben-Weyl Methods of Molecular Transformations*; Molander, G. A., Trost, B. M., Eds.; Thieme: Stuttgart, 2007; Vol. 33, pp 629–658. (c) Inman,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 M.; Moody, C. J. Indole synthesis – something old, something new. *Chem. Sci.* **2013**, *4*, 29–41. (d) Ning, Y.; Zhao, X.-F.; Wu, Y.-B.; Bi, X. Radical
4 Enamination of Vinyl Azides: Direct Synthesis of *N*-Unprotected Enamines. *Org. Lett.* **2017**, *19*, 6240–6243.
5
6 (14) Lee, J.-H.; Cho, C.-G. Total Synthesis of (–)-Neocosmosin A via Intramolecular Diels–Alder Reaction of 2-Pyrone. *Org. Lett.* **2016**, *18*, 5126–
7 5129.
8
9 (15) Smith, B. C.; Underbakke, E. S.; Kulp, D. W.; Schief, W. R.; Marletta, M. A. Nitric oxide synthase domain interfaces regulate electron transfer
10 and calmodulin activation. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, E3577–E3586.
11
12 (16) Han, A.-R.; Kang, Y.-J.; Windono, T.; Lee, S. K.; Seo, E.-K. Prenylated Flavonoids from the Heartwood of *Artocarpus communis* with Inhibitory
13 Activity on Lipopolysaccharide-Induced Nitric Oxide Production. *J. Nat. Prod.* **2006**, *69*, 719–721.
14
15 (17) Arp, F. O.; Fu, G. C. Catalytic Enantioselective Negishi Reactions of Racemic Secondary Benzylic Halides. *J. Am. Chem. Soc.* **2005**, *127*,
16 10482–10483.
17
18 (18) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera—A Visualization
19 System for Exploratory Research and Analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612.
20
21 (19) Forli, S.; Huey, R.; Pique, M. E.; Sanner, M. F.; Goodsell, D. S.; Olson, A. J. Computational protein–ligand docking and virtual drug screening
22 with the AutoDock suite. *Nat. Protoc.* **2016**, *11*, 905–919.
23
24 (20) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated
25 docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60